| Liraglutide and cardiovascular outcomes in type 2 diabetes SP Marso, GH Daniels, et. al. New England Journal of Medicine 375 (4), 311-22, 2016 | 7010 | 2016 |
| Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial S Del Prato, SE Kahn, I Pavo, GJ Weerakkody, Z Yang, J Doupis, ... The Lancet 398 (10313), 1811-1824, 2021 | 349 | 2021 |
| Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy M Grossmann, EJ Hamilton, C Gilfillan, D Bolton, DL Joon, JD Zajac Med J Aust 194 (6), 301-306, 2011 | 123 | 2011 |
| The high burden of inpatient diabetes mellitus: the Melbourne Public Hospitals Diabetes Inpatient Audit LA Bach, EI Ekinci, D Engler, C Gilfillan, PS Hamblin, RJ MacIsaac, ... Medical Journal of Australia 201 (6), 334-338, 2014 | 92 | 2014 |
| Fracture prevention strategies in patients presenting to Australian hospitals with minimal‐trauma fractures: a major treatment gap HJ Teede, IA Jayasuriya, CP Gilfillan Internal Medicine Journal 37 (10), 674-679, 2007 | 66 | 2007 |
| A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia CP Gilfillan, BJS Strauss, CP Rodda, DK Bowden, AM Kean, M Obaid, ... Calcified tissue international 79, 138-144, 2006 | 49 | 2006 |
| The control of ovulation in mothers of dizygotic twins. CP Gilfillan, DM Robertson, HG Burger, MA Leoni, VA Hurley, NG Martin The Journal of Clinical Endocrinology & Metabolism 81 (4), 1557-1562, 1996 | 43 | 1996 |
| Real-world artificial intelligence-based opportunistic screening for diabetic retinopathy in endocrinology and indigenous healthcare settings in Australia J Scheetz, D Koca, M McGuinness, E Holloway, Z Tan, Z Zhu, R O’day, ... Scientific Reports 11 (1), 15808, 2021 | 40 | 2021 |
| Development and validation of a radioimmunoassay for follistatin in human serum CP Gilfillan, DM Robertson Clinical Endocrinology 41 (4), 453-461, 1994 | 37 | 1994 |
| Mitochondrial disease: an uncommon but important cause of diabetes mellitus ML Yee, R Wong, M Datta, TN Fazio, MM Ebrahim, EC Mcnamara, ... Endocrinology, Diabetes & Metabolism Case Reports 2018 (1), 2018 | 31 | 2018 |
| Review of the genetics of thyroid tumours: diagnostic and prognostic implications CP Gilfillan ANZ Journal of Surgery 80 (1‐2), 33-40, 2010 | 29 | 2010 |
| Determinants of forearm mineral density and its correlation with fracture history in women CP Gilfillan, S Silberberg, P Scrivenor, RC Griffiths, PI McCloud, ... Maturitas 20 (2-3), 199-208, 1994 | 23 | 1994 |
| Leukocyte telomere length in the neonatal offspring of mothers with gestational and pre-gestational diabetes C Gilfillan, P Naidu, F Gunawan, F Hassan, P Tian, N Elwood PloS one 11 (10), e0163824, 2016 | 22 | 2016 |
| Nuclear receptor expression in human differentiated thyroid tumors M Mond, M Alexiadis, N Eriksson, MJ Davis, GEO Muscat, PJ Fuller, ... Thyroid 24 (6), 1000-1011, 2014 | 20 | 2014 |
| Subclinical hypothyroidism during pregnancy: the Melbourne public hospitals consensus PS Hamblin, PM Sheehan, C Allan, CA Houlihan, ZX Lu, SP Forehan, ... Internal medicine journal 49 (8), 994-1000, 2019 | 18 | 2019 |
| Somatic Mutations of FOXE1 in Papillary Thyroid Cancer M Mond, M Bullock, Y Yao, RJ Clifton-Bligh, C Gilfillan, PJ Fuller Thyroid 25 (8), 904-910, 2015 | 18 | 2015 |
| Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial J Proietto, J Malloy, D Zhuang, M Arya, ND Cohen, FJ de Looze, ... Diabetologia 61, 1918-1922, 2018 | 17 | 2018 |
| ‘First, do no harm’: managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer AJ Lomax, P Parente, C Gilfillan, PM Livingston, ID Davis, C Pezaro Internal Medicine Journal 46 (2), 141-148, 2016 | 17 | 2016 |
| A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes F Curtin, B Champion, P Davoren, S Duke, EI Ekinci, C Gilfillan, C Morbey, ... Diabetes, Obesity and Metabolism 22 (7), 1111-1121, 2020 | 13 | 2020 |
| Building the evidence for integrated care for type 2 diabetes: a pilot study JL Browne, J Speight, C Martin, C Gilfillan Australian journal of primary health 22 (5), 409-415, 2016 | 13 | 2016 |
